Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection

Drug and Alcohol Dependence

Volumn 88, Issue SUPPL. 2, 2007, Pages

  Rosenberg, Eric S ^a,b   Davidian, Marie ^b   Banks, H Thomas ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

CD4; Drug resistance; HIV dynamics; STI; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BIOLOGICAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION CONTROL; LONG TERM CARE; MATHEMATICAL MODEL; PRIORITY JOURNAL; SUBSTANCE ABUSE; TREATMENT PLANNING; TREATMENT WITHDRAWAL;

ANTIGENS, CD4; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34047154061     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.12.024     Document Type: Article

References (73)

1. Adams B.M., Banks H.T., Davidian M., Kwon H.D., Tran H.T., Wynne S.N., and Rosenberg E.S. HIV dynamics: modeling, data analysis, and optimal treatment protocols. J. Comp. Appl. Math. 184 (2005) 10-49
2. Adams B.M., Banks H.T., Davidian M., and Rosenberg E.S. Estimation and prediction with HIV-treatment interruption data. Bull. Math. Bio. 69 (2007) 563-584
3. Adams B.M., Banks H.T., Kwon H.D., and Tran H.T. Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng. 1 (2004) 223-242
4. Anderson B.D.O., and Moore J.B. Optimal Control: Linear Quadratic Methods (1990), Prentice-Hall, Englewood Cliffs, NJ
5. Antinori A., Cingolani A., and Perno C.F. Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy?. AIDS 19 (2005) 1691-1694
6. Banks H.T., and Kunisch K. Estimation Techniques for Distributed Parameter Systems (1989), Birkhauser, Boston
7. Banks H.T., Kwon H.D., Toivanen J.A., and Tran H.T. An SDRE based estimator approach for HIV feedback control. J. Opt. Cont. Appl. Math 27 (2006) 91-121
8. Brandt M.E., and Chen G. Feedback control of a biodynamical model of HIV-1. IEEE Trans. Biomed. Eng. 48 (2001) 754-759
9. Camacho E.F., and Bordons C. Model Predictive Control (2004), Springer-Verlag, London
10. Chene G., Sterne A.J., May M., Costagliola D., Ledergerber B., Phillips A., Dabis F., Lundgren J., D'Arminio Monforte A., de Wolf F., Hogg R., Reiss P., Justice A., Leport C., Staszewski S., Gill J., Fatkenheuer G., and Egger M. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362 (2003) 679-686
11. Collins L.M., Murphy S.A., and Bierman K.L. A conceptual framework for adaptive preventive interventions. Prev. Sci. 5 (2004) 185-196
12. Croteau G., Doyon L., Thibeault D., McKercher G., Pilote L., and Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71 (1997) 1089-1096
13. Culshaw R.V., Ruan S., and Spiteri R.J. Optimal HIV treatment by maximising immune response. J. Math. Bio. 48 (2004) 545-562
14. Davidian M., and Giltinan D.M. Nonlinear Models for Repeated Measurement Data (1995), Chapman & Hall/CRC Press, New York
15. Davidian M., and Giltinan D.M. Nonlinear models for repeated measurement data: an overview and update. J. Agricult. Bio. Environ. Stat. 8 (2003) 387-419
16. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., and Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344 (2001) 472-480
17. Detels R., Munoz A., McFarlane G., Kingsley L.A., Margolick J.B., Giorgi J., Schrager L.K., and Phair J.P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280 (1998) 1497-1503
18. DHHS, 2005. U.S. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at http://www.aidsinfo.nih.gov (last accessed 4/3/06).
19. Di Mascio M., Riberio R.M., Markowitz M., Ho D.D., and Perelson A.S. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math. Biosci. 188 (2004) 47-62
20. Dixit N.M., and Perelson A.S. Complex patterns of viral load decay under antiretroviral Erhart: influence of pharmacokinetics and intracellular delay. J. Theor. Bio. 226 (2004) 95-109
21. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., Oxenius A., Price D.A., Connors M., and Koup R.A. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 (2002) 95-98
22. Egger M., May M., Chene G., Phillips A.N., Ledergerber B., Dabis F., Costagliola D., D'Arminio Monforte A., de Wolf F., Reiss P., Lundgren J.D., Justice A.C., Staszewski S., Leport C., Hogg R.S., Sabin C.A., Gill M.J., Salzberger B., and Sterne J.A. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
23. El-Sadr W., Neaton J., and for the SMART Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. Abstract #106LB. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February (2006)
24. Finney J.W., Hahn A.C., and Moos R.H. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 91 (1996) 1803-1820
25. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., and Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5 (1999) 512-517
26. Ghosn J., Wirden M., Ktorza N., Peytavin G., Ait-Mohand H., Schneider L., Dominguez S., Bricaire F., Calvez V., Costagliola D., and Katlama C. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 19 (2005) 1643-1647
27. Hairer E., and Wanner G. Solving Ordinary Differential Equations II. Stiff and Differential-Algebraic Problems, vol. 14, Springer Series in Computational Mathematics. 2nd ed. (1996), Springer-Verlag, Berlin
28. Hindmarsh A.C. Scientific Computing, Chapter on ODEPACK, A Systematized Collection of ODE Solvers (1983), North Holland, New York pp. 55-64
29. Hirschel B. Planned interruptions of anti-HIV treatment. Lancet Infect. Dis. 1 (2001) 53-59
30. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1996) 123-126
31. Hser Y.I., Anglin M.D., Grella C., Longshore D., and Prendergast M.L. Drug treatment careers: a conceptual framework and existing research findings. J. Subst. Abuse Treat. 14 (1997) 543-558
32. Jeffrey A.M., Xia X., and Craig I.K. When to initiate HIV therapy: a control theoretic approach. IEEE Trans. Biomed. Eng. 50 (2003) 1213-1220
33. Kassutto S., and Rosenberg E.S. Primary HIV type 1 infection. Clin. Infect. Dis. 38 (2004) 1447-1453
34. Katlama C., Dominguez S., Gourlain K., Duvivier C., Delaugerre C., Legrand M., Tublana R., Reynes J., Molina J.M., Peytavin G., Calvez V., and Costagliola D. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18 (2004) 217-226
35. Kaufmann D.E., Lichterfeld M., Altfeld M., Addo M.M., Johnston M.N., Lee P.K., Wagner B.S., Kalifer E., Strick D., Rosenberg E.S., and Walker B.D. Limited durability of viral control following treated acute HIV infection. PLoS Med. 1 (2004) e36
36. Kelley C.T. Iterative methods for optimization. Frontiers in Applied Mathematics FR18 (1999), SIAM, Philadelphia
37. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Waters E.E., and Wang P.S. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 289 (2003) 3095-3105
38. Kirschner D., Lenhart S., and Serbin S. Optimal control of the chemotherapy of HIV. J. Math. Bio. 35 (1997) 775-792
39. Lavori P.W., and Dawson R. Dynamic treatment regimes: practical design considerations. Clin. Trials 1 (2003) 9-20
40. Lawrence J., Mayers D.L., Hullsiek K.H., Collins G., Abrams D.I., Reisler R.B., Crane L.R., Schmetter B.S., Dionne T.J., Saldanha J.M., Jones M.C., and Baxter J.D. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 349 (2003) 837-846
41. Ledergerber B., Egger M., Opravil M., Telenti A., Hirschel B., Battegay M., Vernazza P., Sudre P., Flepp M., Furrer H., Francioli P., and Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353 (1999) 863-868
42. Lisziewicz J., Rosenberg E., Lieberman J., Jessen H., Lopalco L., Siliciano R., Walker B., and Lori F. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340 (1999) 1683-1684
43. Lori F., Lewis M.G., Xu J., Varga G., Zinn D.E., Crabbs C., Wagner W., Greenhouse J., Silvera P., Yally-Ogunro J., Tinelli C., and Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early infection. Science 290 (2000) 1591-1593
44. Lori F., and Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 286 (2001) 2981-2987
45. Lyles R.H., Munoz A., Yamashita T.E., Bazmi H., Detels R., Rinaldo C.R., Margolick J.B., Phair J.P., Mellors J.W., and for the Multicenter AIDS Cohort Study. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J. Infect. Dis. 181 (2000) 872-880
46. Martinez E., Mocroft A., Garcia-Viejo M.A., Perez-Cuevas J.B., Blanco J.L., Mallolas J., Bianchi L., Conget I., Blanch J., Phillips A., and Gatell J.M. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357 (2001) 592-598
47. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., Kumar P.N., Mintz L., Wallach F.R., and Nemo G.J. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135 (2001) 17-26
48. Murphy S.A. An experimental design for the development of adaptive treatment strategies. Stat. Med. 24 (2005) 1455-1481
49. Murphy S.A., Oslin D.W., Rush A.J., and Zhu J. Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology 32 (2007) 257-262
50. Nijhuis M., Deeks S., and Boucher C. Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 14 (2001) 23-28
51. Oxenius A., Price D.A., Easterbrook P.J., O'Callaghan C.A., Kelleher A.D., Whelan J.A., Sontag G., Sewell A.K., and Phillips R.E. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3382-3387
52. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 (1998) 853-860
53. Palella Jr. F.J., Deloria-Knoll M., Chmiel J.S., Moorman A.C., Wood K.C., Greenberg A.E., and Holmberg S.D. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138 (2003) 620-626
54. Perelson A.S., Essunger P., Cao Y.Z., Vesanen M., Hurley A., Saksela K., Markowitz M., and Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
55. Phillips A.N., Dunn D., Sabin C., Pozniak A., Matthias R., Geretti A.M., Clarke J., Churchill D., Williams I., Hill T., Green H., Porter K., Scullard G., Johnson M., Easterbrook P., Gilson R., Fisher M., Loveday C., Gazzard B., and Pillay D. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19 (2005) 487-494
56. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 393-401
57. Rivera D.E., Pew M.D., and Collins L.M. Using engineering control principles to inform the design of adaptive interventions: a conceptual introduction. Drug Alcohol Depend. 88S (2007) S31-S40
58. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B., Eldridge R.L., Robbins G.K., D'Aquila R.D., Goulder P.J.R., and Walker B.D. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
59. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., and Walker B.D. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 (1997) 1447-1450
60. Ruiz L., Martinez-Picado J., Romeu J., Paredes R., Zayat M.K., Marfil S., Negredo E., Sirera G., Tural C., and Clotet B. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 1 (2000) 397-403
61. Ruiz L., Ribera E., Bonjoch A., Romeu J., Martinez-Picado J., Paredes R., Diaz M., Marfil S., Negredo E., Garcia-Prado J., Tural C., Sirera G., and Clotet B. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J. Infect. Dis. 188 (2003) 977-985
62. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., and Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9 (2003) 727-728
63. Smith K.Y. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J. Infect. Dis. 185 (2002) S123-S127
64. Sobell M.B., and Sobell L.C. Stepped care as a heuristic approach to the treatment of alcohol problems. J. Consult. Clin. Psychol. 68 (2000) 573-579
65. Sterling T.R., Chaisson R.E., Keruly J., and Moore R.D. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J. Infect. Dis. 188 (2003) 1659-1665
66. Streeck H., Jessen H., Adler G., Teigen N., Waring M.T., Jessen A., Stahmer I., van Lunzen J., Lichterfeld M., Gao X., Allen T.M., Carrington M., Walker B.D., Rockstroh J.K., and Altfeld M. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J. Infect. Dis. 194 (2006) 734-739
67. Vogel C.R. Computational Methods for Inverse Problems, Frontiers in Applied Mathematics FR23 (2002), SIAM, Philadelphia
68. Walker B.D., and Rosenberg E.S. Containing HIV after infection. Nat. Med. 6 (2000) 1094-1095
69. Wein L.M., Zenios S.A., and Nowak M.A. Dynamic multidrug therapies for HIV: a control theoretic approach. J. Theor. Biol. 185 (1997) 14-29
70. Wodarz D., Arnaout R.A., Nowak M.A., and Lifson J.D. Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus. Phil. Trans. Roy. Soc. Lond. B 355 (2000) 1021-1029
71. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., and Montaner J.S. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann. Intern. Med. 139 (2003) 810-816
72. Wood E., Hogg R.S., Yip B., Quercia R., Harrigan P.R., O'Shaughnessy M.V., and Montaner J.S. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J. Infect. Dis. 188 (2003) 1421-1425
73. Yeni P.G., Hammer S.M., Hirsch M.S., Saag M.S., Schechter M., Carpenter C.C., Fischl M.A., Gatell J.M., Gazzard B.G., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Schooley R.T., Thompson M.A., Vella S., and Volberding P.A. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292 (2004) 251-265